RingConn secures US FDA clearance for smart ring blood oxygen monitor
Technology manufacturer Shenzhen Ninenovo received 510 k regulatory clearance from the US Food and Drug Administration for non invasive blood oxygen tracking on its RingConn smart ring
Shenzhen Ninenovo Technology, the parent company of RingConn, announced on October 10, 2026 that its Smart Ring received FDA clearance for non-invasive blood oxygen (SpO2) measurement. The 510(k) clearance, No. K260490, signifies a significant achievement for RingConn in the FDA-cleared wearable health devices market. The FDA determined the RingConn Smart Ring to be substantially equivalent to legally marketed predicate devices for non-invasive SpO2 measurement, granting compliance assurance for the company's expansion into the U.S. healthcare and wellness market.
Blood oxygen (SpO2) is a crucial indicator of respiratory and circulatory function, and continuous monitoring offers valuable insights into one's daily health and physiological condition. RingConn achieves non-invasive SpO2 measurement through PPG sensor technology and other innovations, integrating advanced monitoring capabilities into a wearable form factor.
The company continues to conduct clinical research to build a solid data foundation for clinical validation. RingConn has already obtained various international certifications, including EU CE, U.S. FCC, Japan MIC, UK UKCA, and Australia RCM, and the product is available in over 190 countries and regions.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
